Opportunity
SAM #75N98026Q00212
Sole Source Next Generation Sequencing Services for NHLBI Clinical Research
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
April 15, 2026
Respond By
April 20, 2026
Identifier
75N98026Q00212
NAICS
541380, 541714, 541715
The National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) is seeking specialized Next Generation Sequencing (NGS) services for clinical research on bone marrow failure syndromes and hematologic disorders. - Government Buyer: - National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Hematology Branch - OEM and Vendor: - Genomic Testing Cooperative (GTC) is the sole source vendor and OEM for the required NGS services - Products/Services Requested: - Next Generation Sequencing (NGS) services to analyze approximately 16 patient samples - Sequencing of a panel covering about 302 genes associated with hematologic neoplasms - Processing of multiple sample types: plasma, fresh cells, and FFPE tissue - Sequencing of coding DNA regions, detection of insertions, deletions, structural variants - Fragment length analysis for CALR, FLT3, NPM1 genes - Capability to process low DNA input samples - Secure electronic delivery of results - Turnaround time of 7-10 days per sample - Unique or Notable Requirements: - Continuity with existing data and unique technical capabilities of GTC are required - Results must be delivered within 7-10 days after receipt of each sample - Services must support clinical research for bone marrow failure syndromes - Place of Performance: - Lake Forest, California (Genomic Testing Cooperative facility) - The notice is not a request for competitive quotations, but capability statements may be submitted for consideration
Description
The National Heart, Lung, and Blood Institute (NHLBI) intends to award a sole source purchase order to Genomic Testing Cooperative (GTC) for Next Generation Sequencing (NGS) services. These services will support clinical research by analyzing patient samples to detect somatic genetic mutations associated with bone marrow failure syndromes.
This notice is not a request for competitive quotations. Interested parties may submit a capability statement for consideration. See attached Notice of Intent for additional details.